MSB

2.58%

94.5¢ mesoblast limited

FDA ODAC Meeting Material discussion analysis, page-61

First 61 Last

Share
Profile

Follow
whenwill

170 Posts.

489

11/08/20

20:07

Post #: 46465073
Share

Originally posted by JB1975: ↑

"Overall, I'm quite satisfied with MSB's responses addressing FDA's concerns."

With respect I think you are reading the timeline backwards. What you are referring to as FDA concerns are arising after not before reading MSB's briefing material in my opinion.

For example consider the statement from the 10 page FDA Briefing Document on page 4 -

"The Applicant has defined critical quality attributes (CQAs) for remestemcel-L that are proposed to be related to the potency and activity of the product (see Section 5.1 Critical Quality Attributes in the Applicant's briefing document)."

The FDA could not make those sort of references if they hadn't already read Mesoblast briefing document (or at least a draft of it that was pretty close to complete).

The way you have structured you post suggests to me that you believe Mesoblast has already responded to the FDA concerns in their briefing - it seems to me you have the order the wrong way around. To me it seems like the FDA have responded to the briefing with concerns and questions and those now need Mesoblast and/or the advisory committee to address them.

For instance continuing on from the quote above I see this statement -
"FDA's position is that the product attributes the Applicant has identified as related to potency and activity, however, do not have a demonstrated relationship to the clinical performance of specific DP lots, and that the product's proposed immunomodulatory mechanism of action has not been demonstrated in vivo in study subjects receiving remenstemcel-L. Without a demonstrated relationship with clinical effectiveness and/or in vivo potency/activity, controlling these CQAs may not be sufficient to ensure the manufacturing process consistently produces remenstemcel-L lots of acceptable quality".

Expand

I wasn't sure of that on first reading, so thanks for pointing that out.

I'm not sure flipping the order, i.e. FDA saying, "We've read your briefing, now explain it further and answer these questions" changes much in terms of Mesoblast's approach to the meeting. If anything, they've got about 2 days to gather more evidence and answer with confidence!

MSB Price at posting: $3.36 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

CBA breaks trading record on strong day for Aussie financials

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

As Nvidia cools, we're looking to Aussie AI

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

There are more pages in this discussion • 431 more messages in this thread...

First 61 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 94.5¢		Change -0.025(2.58%)		Mkt cap ! $1.078B

Open	High	Low	Value	Volume
98.0¢	98.5¢	94.0¢	$2.482M	2.602M

Buyers (Bids)

No.	Vol.	Price($)
6	71720	94.0¢

Sellers (Offers)

Price($)	Vol.	No.
94.5¢	10463	1

View Market Depth

No.	Vol.	Price($)
5	65720	0.940
3	31070	0.935
4	85753	0.930
2	9000	0.925
5	75776	0.920

Price($)	Vol.	No.
0.945	10463	1
0.950	50000	2
0.955	64000	1
0.960	30220	3
0.965	44050	3

Last trade - 16.10pm 06/09/2024 (20 minute delay)

MSB (ASX) Chart

FDA ODAC Meeting Material discussion analysis, page-61

CBA breaks trading record on strong day for Aussie financials

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Shekel Brainweigh investor presentation webinar – the future of retail automation

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

As Nvidia cools, we're looking to Aussie AI

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA ODAC Meeting Material discussion analysis, page-61

Top Stories

CBA breaks trading record on strong day for Aussie financials

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Shekel Brainweigh investor presentation webinar – the future of retail automation

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

As Nvidia cools, we're looking to Aussie AI

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News